Literature DB >> 15310769

Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection.

Robert J Downey1, Timothy Akhurst, Mithat Gonen, Alain Vincent, Manjit S Bains, Steven Larson, Valerie Rusch.   

Abstract

PURPOSE: A retrospective review of surgically treated lung cancer patients imaged preoperatively by F-18 fluorodeoxyglucose-positron emission tomography ([(18)F]FDG-PET) to determine if the primary tumor standardized uptake value (SUV) predicts survival. PATIENTS AND METHODS: Non-small-cell lung cancer or carcinoid pT1-4, N0-2, M0 patients treated by R0 surgical resection alone were imaged with computed tomography scan and PET within 90 days before surgery. Prognostic variables were assessed by log-rank test; survival was assessed by the method of Kaplan and Meier.
RESULTS: One hundred consecutive patients (48 men, 52 women) were retrospectively reviewed. Median follow-up for surviving patients was 28 months (range, 16 to 81 months). Median maximal SUV (SUV(MAX)) was 9. The 2-year survival for patients with SUV(MAX) more than 9 was 68% and for those with SUV(MAX) less than 9, it was 96% (P <.01, log-rank test). In a multivariate analysis including pathologic tumor size, involved nodes, histology, and SUV(MAX), only tumor size (T) more than 3 cm and SUV(MAX) more than 9 and their interaction were significant predictors of survival (P =.01, 0.02, and < 0.01, respectively). The 3-year survivals for patients with both T less than 3 cm and SUV(MAX) less than 9 was 97%; for those with T less than 3 cm and SUV(MAX) more than 9, it was 94%; for those with T more than 3 cm and SUV(MAX) less than 9, it was 93%; and for those with T more than 3 cm and SUV(MAX) more than 9, it was 47% (P <.01).
CONCLUSION: In surgically managed lung cancer patients, SUV is a predictor of overall survival after resection. The addition of SUV(MAX) to pathologic tumor size identifies a subgroup of patients at highest risk for death as a result of recurrent disease after resection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15310769     DOI: 10.1200/JCO.2004.11.109

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  92 in total

Review 1.  Molecular imaging for personalized cancer care.

Authors:  Moritz F Kircher; Hedvig Hricak; Steven M Larson
Journal:  Mol Oncol       Date:  2012-03-10       Impact factor: 6.603

2.  Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection.

Authors:  Kojun Okamoto; Isamu Koyama; Mitsuo Miyazawa; Yasuko Toshimitsu; Masayasu Aikawa; Katsuya Okada; Etsuko Imabayashi; Hiroshi Matsuda
Journal:  Int J Clin Oncol       Date:  2010-09-23       Impact factor: 3.402

3.  FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma.

Authors:  Kyuichi Kadota; Christos Colovos; Kei Suzuki; Nabil P Rizk; Mark P S Dunphy; Emily C Zabor; Camelia S Sima; Akihiko Yoshizawa; William D Travis; Valerie W Rusch; Prasad S Adusumilli
Journal:  Ann Surg Oncol       Date:  2012-05-30       Impact factor: 5.344

4.  Prognostic value of fluorine-18 fludeoxyglucose positron emission tomography parameters differs according to primary tumour location in small-cell lung cancer.

Authors:  Tomomi Nobashi; Sho Koyasu; Yuji Nakamoto; Takeshi Kubo; Takayoshi Ishimori; Young H Kim; Akihiko Yoshizawa; Kaori Togashi
Journal:  Br J Radiol       Date:  2016-01-12       Impact factor: 3.039

5.  Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.

Authors:  Dirk Hellwig; Andreas Gröschel; Thomas P Graeter; Anne P Hellwig; Ursula Nestle; Hans-Joachim Schäfers; Gerhard W Sybrecht; Carl-Martin Kirsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-09       Impact factor: 9.236

6.  Correlation of PET/CT standardized uptake value measurements between dedicated workstations and a PACS-integrated workstation system.

Authors:  Gustavo S P Meirelles; Peter Kijewski; Timothy Akhurst
Journal:  J Digit Imaging       Date:  2007-09       Impact factor: 4.056

7.  Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer.

Authors:  Gustavo S P Meirelles; Heiko Schöder; Gregory C Ravizzini; Mithat Gönen; Josef J Fox; John Humm; Michael J Morris; Howard I Scher; Steven M Larson
Journal:  Clin Cancer Res       Date:  2010-10-25       Impact factor: 12.531

8.  Preoperative [18F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer.

Authors:  Hyun Hoon Chung; Byung-Ho Nam; Jae Weon Kim; Keon Wook Kang; Noh-Hyun Park; Yong-Sang Song; June-Key Chung; Soon-Beom Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-30       Impact factor: 9.236

9.  PET-CT in the staging and treatment of non-small-cell lung cancer.

Authors:  Patricia Ibeas; Blanca Cantos; José Manuel Gasent; Begoña Rodríguez; Mariano Provencio
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

10.  False positive diagnosis of malignancy in a case of cryptogenic organising pneumonia presenting as a pulmonary mass with mediastinal nodes detected on fluorodeoxyglucose-positron emission tomography: a case report.

Authors:  Aravind Ponnuswamy; Neeraj Mediratta; Iain D Lyburn; James P Finnerty
Journal:  J Med Case Rep       Date:  2009-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.